21 research outputs found
Home-based hepatitis C self-testing in people who inject drugs and men who have sex with men in Georgia: a protocol for a randomised controlled trial
Introduction Globally, it is estimated that more than three-quarters of people with chronic hepatitis C virus (HCV) are unaware of their HCV status. HCV self-testing (HCVST) may improve access and uptake of HCV testing particularly among key populations such as people who inject drugs (PWID) and men who have sex with men (MSM) where HCV prevalence and incidence are high and barriers to accessing health services due to stigma and discrimination are common.
Methods and analysis This randomised controlled trial compares an online programme offering oral fluid-based HCVST delivered to the home with referral to standard-of-care HCV testing at HCV testing sites. Eligible participants are adults self-identifying as either MSM or PWID who live in Tbilisi or Batumi, Georgia, and whose current HCV status is unknown. Participants will be recruited through an online platform and randomised to one of three arms for MSM (courier delivery, peer delivery and standard-of-care HCV testing (control)) and two for PWID (peer delivery and standard-of-care HCV testing (control)). Participants in the postal delivery group will receive an HCVST kit delivered by an anonymised courier. Participants in the peer delivery groups will schedule delivery of the HCVST by a peer. Control groups will receive information on how to access standard-of-care testing at a testing site. The primary outcome is the number and proportion of participants who report completion of testing. Secondary outcomes include the number and proportion of participants who (a) receive a positive result and are made aware of their status, (b) are referred to and complete HCV RNA confirmatory testing, and (c) start treatment. Acceptability, feasibility, and attitudes around HCV testing and cost will also be evaluated. The target sample size is 1250 participants (250 per arm)
Securing sustainable funding for viral hepatitis elimination plans
The majority of people infected with chronic hepatitis C
virus (HCV) in the European Union (EU) remain undiagnosed and
untreated. During recent years, immigration to EU has further
increased HCV prevalence. It has been estimated that, out of the
4.2 million adults affected by HCV infection in the 31 EU/
European Economic Area (EEA) countries, as many as
580\xC2\xA0000 are migrants. Additionally, HCV is highly
prevalent and under addressed in Eastern Europe. In 2013, the
introduction of highly effective treatments for HCV with
direct-acting antivirals created an unprecedented opportunity to
cure almost all patients, reduce HCV transmission and eliminate
the disease. However, in many settings, HCV elimination poses a
serious challenge for countries' health spending. On 6 June
2018, the Hepatitis B and C Public Policy Association held the
2nd EU HCV Policy summit. It was emphasized that key
stakeholders should work collaboratively since only a few
countries in the EU are on track to achieve HCV elimination by
2030. In particular, more effort is needed for universal
screening. The micro-elimination approach in specific
populations is less complex and less costly than country-wide
elimination programmes and is an important first step in many
settings. Preliminary data suggest that implementation of the
World Health Organization (WHO) Global Health Sector Strategy on
Viral Hepatitis can be cost saving. However, innovative
financing mechanisms are needed to raise funds upfront for
scaling up screening, treatment and harm reduction interventions
that can lead to HCV elimination by 2030, the stated goal of the
WHO
The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing
Correction to: Hepatitis C virus infection in EU/EEA and United Kingdom prisons: Opportunities and challenges for action
Hepatitis C virus infection in EU/EEA and United Kingdom prisons: opportunities and challenges for action.
BACKGROUND: Hepatitis C virus (HCV) transmission in the European Union, European Economic Area and United Kingdom is driven by injecting drug use (IDU), which contributes to the high burden of chronic infection among people in prisons. This study aimed to describe the context, epidemiology and response targeting HCV in prisons across the region.
METHODS: We retrieved and collated HCV-related data from the World Health Organization's Health in Prisons European Database and the European Centre for Disease Prevention and Control's hepatitis C prevalence database. Prisons population data were obtained from the Council of Europe Annual Penal Statistics on prison populations (SPACE I).
RESULTS: There were 12 to 93,266 people in prisons, with rates of 31·5 to 234·9 per 100,000 population. Median age was between 31 and 40 years, with up to 72% foreign nationals. Average detention time ranged from one to 31 months. Ministries of Health had sole authority over prisons health, budget administration and funding in 27, 31 and 8% of 26 reporting countries, respectively. Seroprevalence of HCV antibodies ranged from 2·3% to 82·6% while viraemic infections ranged from 5·7% to 8·2%, where reported. Up to 25·8 and 44% reported current and ever IDU, respectively. Eight countries routinely offered HCV screening on an opt-out basis. Needle and syringe programmes were available in three countries. Among the nine countries with data, the annual number of those who had completed HCV treatment ranged between one and 1215 people in prisons.
CONCLUSIONS: HCV burden in prisons remains high, amidst suboptimal levels of interventions. Systematic monitoring at both local and regional levels is warranted, to advance progress towards the elimination of HCV in the region
Additional file 3: of Strengthening hepatitis B and C surveillance in Europe: results from the two global hepatitis policy surveys (2013 and 2014)
Reporting by Member States on the existence of a written national viral hepatitis strategy or plan. (DOCX 30 kb
Rhododendron boninense Nakai
原著和名: ムニンツツジ科名: ツツジ科 = Ericaceae採集地: 東京都 小笠原村 父島 (小笠原村 父島)採集日: 1971/4/3採集者: 萩庭丈壽整理番号: JH043879国立科学博物館整理番号: TNS-VS-99387
Progress toward hepatitis B control : World Health Organization European region, 2016-2019
Prevalence of hepatitis B virus infection among general population of Armenia in 2021 and factors associated with it: a cross-sectional study
Objectives This study sought to determine the prevalence and associated factors of hepatitis B virus (HBV) infection ever in life and chronic HBV infection in Armenia.Design A population-based cross-sectional seroprevalence study combined with a phone survey of tested individuals.Setting All administrative units of Armenia including 10 provinces and capital city Yerevan.Participants The study frame was the general adult population of Armenia aged ≥18 years.Primary and secondary outcome measures The participants were tested for anti-HBV core antibodies (anti-HBc) and HBV surface antigen (HBsAg) using third-generation enzyme immunoassays. In case of HBsAg positivity, HBV DNA and hepatitis D virus (HDV) RNA PCR tests were performed. Risk factors of HBV infection ever in life (anti-HBc positivity) and chronic HBV infection (HBsAg positivity) were identified through fitting logistic regression models.Results The seroprevalence study included 3838 individuals 18 years and older. Of them, 90.7% (3476 individuals) responded to the phone survey. The prevalence of anti-HBc positivity was 14.1% (95% CI 13.1% to 15.2%) and HBsAg positivity 0.8% (95% CI 0.5% to 1.1%). The viral load was over 10 000 IU/mL for 7.9% of HBsAg-positive individuals. None of the participants was positive for HDV. Risk factors for HBsAg positivity included less than secondary education (aOR=6.44; 95% CI 2.2 to 19.1), current smoking (aOR=2.56; 95% CI 1.2 to 5.6), and chronic liver disease (aOR=8.44; 95% CI 3.0 to 23.7). In addition to these, risk factors for anti-HBc positivity included age (aOR=1.04; 95% CI 1.04 to 1.05), imprisonment ever in life (aOR=2.53; 95% CI 1.41 to 4.56), and poor knowledge on infectious diseases (aOR=1.32; 95% CI 1.05 to 1.67), while living in Yerevan (vs provinces) was protective (aOR=0.74; 95% CI 0.59 to 0.93).Conclusion This study provided robust estimates of HBV markers among general population of Armenia. Its findings delineated the need to revise HBV testing and treatment strategies considering higher risk population groups, and improve population knowledge on HBV prevention
Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery.
BACKGROUND The World Health Organization (WHO) recommends oral pre-exposure prophylaxis (PrEP) for all people at substantial risk of HIV as part of combination prevention. The extent to which this recommendation has been implemented globally for people who inject drugs is unclear. This study mapped global service delivery of PrEP for people who inject drugs.
METHODS Between October and December 2021, a desk review was conducted to obtain information on PrEP services for people who inject drugs from drug user-led networks and HIV, harm reduction, and human rights stakeholders. Websites of organizations involved in HIV prevention or services for people who inject drugs were searched. Models of service delivery were described in terms of service location, provider, and package.
RESULTS PrEP services were identified in 27 countries (15 high-income). PrEP delivery models varied within and across countries. In most services, PrEP services were implemented in healthcare clinics without direct links to other harm reduction services. In three countries, PrEP services were also provided at methadone clinics. In 14 countries, PrEP services were provided through community-based models (outside of clinic settings) that commonly involved peer-led outreach activities and integration with harm reduction services.
CONCLUSIONS This study indicates limited PrEP availability for people who inject drugs. There is potential to expand PrEP services for people who inject drugs within harm reduction programs, notably through community-based and peer-led services. PrEP should never be offered instead of evidence-based harm reduction programs for people who inject drugs; however, it could be offered as an additional HIV prevention choice as part of a comprehensive harm reduction program